Table 1.
Patient Characteristics
| Variables (n=174) |
Average |
|---|---|
| Demographics | |
| Age (years) | 67.6 ±11.6 |
| Sex (male) | 156 (90%) |
| BMI (kg/m2) | 28.7 ± 5.1 |
| Diabetes mellitus | 82 (47%) |
| Resting Heart Rate (bpm) | 65 ± 12 |
| Rate/Pressure Product (per 100 bpm/ mm Hg) | 8473 ± 2294 |
| No ACE/ARB Therapy | 18 (10%) |
| β-blocker Therapy | 168 (97%) |
| Warfarin | 69 (40%) |
| Antiplatelet (ASA or Clopidogrel) | 153 (89%) |
| Digoxin | 67 (39%) |
| Echocardiographic and Electrocardiographic Variables | |
| Ejection Fraction (%) | 27.6 ± 8.9 |
| LV End Diastolic Volume Index (mL/m2) | 87.1 ± 29.1 |
| LV End Systolic Volume Index (mL/m2) | 63.9 ± 25.5 |
| LA Volume Index (mL/m2) | 41.9 ± 15.7 |
| LV Mass Index (g/m2) | 152.1 ± 47.5 |
| QRS Duration (ms) | 136.7 ± 35.5 |
| Laboratory Values | |
| Creatinine (mg/dL) | 1.43 ± 0.9 |
| B-type natriuretic peptide, ng/L | 423.1 ±455.8 |
| Hematocrit (%) | 40.6 ± 4.9 |
| [11C]HED PET Quantification | |
| Global Scale Parameters | |
| Retention Index (%/min) | 4.6 ± 1.7 |
| Distribution Volume (mL/g) | 10.5 ± 4.0 |
| Regional Heterogeneity Parameters (%LV) | |
| Normalized Uptake Defect Score | 27.5 ± 11.1 |
| Distribution Volume Defect Score | 38.0 ±11.4 |
BMI, Body mass index; ACE, Angiotensin-converting enzyme; ARB, Angiotensin II Receptor Blocker; ASA, Acetylsalicylic acid; LV, Left ventricle; LA, Left Atrial;